Published in Aliment Pharmacol Ther on May 15, 2003
A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut (2006) 1.75
Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways. Infect Immun (2006) 1.38
Leukocytapheresis (LCAP) in the management of chronic active ulcerative colitis--results of a randomized pilot trial. Dig Dis Sci (2007) 0.94
Medical treatment of ulcerative colitis. Clin Colon Rectal Surg (2004) 0.86
Uneventful pregnancy and neonatal outcome with tacrolimus in refractory ulcerative colitis. Gut (2005) 0.82
The role of tacrolimus in inflammatory bowel disease: a systematic review. Dig Dis Sci (2006) 0.81
The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease. J Gastroenterol (2010) 0.81
The Ulcerative Colitis Endoscopic Index of Severity More Accurately Reflects Clinical Outcomes and Long-term Prognosis than the Mayo Endoscopic Score. J Crohns Colitis (2015) 0.80
What is left when anti-tumour necrosis factor therapy in inflammatory bowel diseases fails? World J Gastroenterol (2014) 0.79
Management of acute severe ulcerative colitis. World J Gastrointest Pathophysiol (2014) 0.79
A higher dose requirement of tacrolimus in active Crohn's disease may be related to a high intestinal P-glycoprotein content. Dig Dis Sci (2005) 0.78
Newer Therapies for Inflammatory Bowel Disease. Curr Treat Options Gastroenterol (2004) 0.77
Local immune regulation of mucosal inflammation by tacrolimus. Dig Dis Sci (2009) 0.77
Novel topical therapies for distal colitis. World J Gastrointest Pharmacol Ther (2010) 0.76
Tacrolimus for the Treatment of Ulcerative Colitis. Intest Res (2015) 0.76
Tacrolimus--finally! Gut (2006) 0.75
B Cell-Activating Factor (BAFF)-Targeted B Cell Therapies in Inflammatory Bowel Diseases. Dig Dis Sci (2016) 0.75
FK506-Binding Protein 5 mRNA Levels in Ileal Mucosa Are Associated with Pouchitis in Patients with Ulcerative Colitis. Dig Dis Sci (2015) 0.75
Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands. Nat Biotechnol (2001) 11.41
Identification and localization of synaptophysin, an integral membrane glycoprotein of Mr 38,000 characteristic of presynaptic vesicles. Cell (1985) 6.06
TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch (2006) 5.86
TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch (2007) 3.89
Transport route for synaptobrevin via a novel pathway of insertion into the endoplasmic reticulum membrane. EMBO J (1995) 2.96
Clathrin-coated vesicles contain an ATP-dependent proton pump. Proc Natl Acad Sci U S A (1983) 2.84
Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol (2004) 2.54
Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology (2005) 2.49
Somatostatin-receptor imaging of neuroendocrine gastroenteropancreatic tumors. Gastroenterology (1993) 2.29
Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells. Cancer Res (2000) 1.90
Magnetic resonance cholangiopancreatography-guided unilateral endoscopic stent placement for Klatskin tumors. Gastrointest Endosc (2001) 1.90
Molecular characterization of synaptophysin, a major calcium-binding protein of the synaptic vesicle membrane. EMBO J (1986) 1.73
LI-cadherin: a marker of gastric metaplasia and neoplasia. Gut (2001) 1.72
Pancreatic carcinoma. Lancet (1997) 1.72
Synaptophysin: a marker protein for neuroendocrine cells and neoplasms. Proc Natl Acad Sci U S A (1986) 1.70
TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst (2012) 1.65
Role of stress in functional gastrointestinal disorders. Evidence for stress-induced alterations in gastrointestinal motility and sensitivity. Dig Dis (2001) 1.63
Health-related quality of life in patients with pancreatic cancer. Digestion (2006) 1.57
[S3-Guidelines "Exocrine pancreatic cancer" 2007]. Z Gastroenterol (2007) 1.52
Synaptophysin expression in neuroendocrine neoplasms as determined by immunocytochemistry. Am J Pathol (1987) 1.51
The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model. Gut (2008) 1.49
Management and outcomes of haemorrhage after pancreatogastrostomy versus pancreatojejunostomy. Br J Surg (2011) 1.46
Pancreatic acinar cell carcinoma. An analysis of cell lineage markers, p53 expression, and Ki-ras mutation. Am J Pathol (1993) 1.39
Epithelial cell-derived components induce transforming growth factor-alpha mRNA expression and epithelial cell proliferation in vitro. Eur J Gastroenterol Hepatol (2001) 1.39
Escherichia coli strain Nissle 1917 ameliorates experimental colitis via toll-like receptor 2- and toll-like receptor 4-dependent pathways. Infect Immun (2006) 1.38
De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. Gastroenterology (2000) 1.37
Topogenesis and sorting of synaptophysin: synthesis of a synaptic vesicle protein from a gene transfected into nonneuroendocrine cells. Cell (1989) 1.32
Dual mechanism of vascular endothelial growth factor upregulation by hypoxia in human hepatocellular carcinoma. Gut (2001) 1.32
Patients with active inflammatory bowel disease lack immature peripheral blood plasmacytoid and myeloid dendritic cells. Gut (2005) 1.27
A novel function for the tumor suppressor p16(INK4a): induction of anoikis via upregulation of the alpha(5)beta(1) fibronectin receptor. J Cell Biol (2000) 1.26
Evaluation of endocytoscopy in the surveillance of patients with Barrett's esophagus. Endoscopy (2007) 1.24
Differentiation of pluripotent embryonic stem cells into the neuronal lineage in vitro gives rise to mature inhibitory and excitatory neurons. Mech Dev (1995) 1.24
Mutations in the E2-PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment. Hepatology (2000) 1.23
Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2. Gut (1996) 1.22
Regulatory peptide receptors in human hepatocellular carcinomas. Gut (1999) 1.22
HIF-1alpha determines the metastatic potential of gastric cancer cells. Br J Cancer (2009) 1.17
Modulation of intestinal epithelial wound healing in vitro and in vivo by lysophosphatidic acid. Gastroenterology (1999) 1.16
Mechanisms of diarrhea in the interleukin-2-deficient mouse model of colonic inflammation. Am J Physiol Gastrointest Liver Physiol (2004) 1.12
Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas. Gut (1996) 1.10
Helicobacter pylori activates the histidine decarboxylase promoter through a mitogen-activated protein kinase pathway independent of pathogenicity island-encoded virulence factors. J Biol Chem (2000) 1.09
Molecular mechanisms of enteroendocrine differentiation. Ann N Y Acad Sci (1998) 1.09
Interferon gamma inhibits growth of human pancreatic carcinoma cells via caspase-1 dependent induction of apoptosis. Gut (2001) 1.07
Solubilization of proteins from bovine brain coated vesicles by protein perturbants and Triton X-100. J Cell Biol (1985) 1.07
Synaptophysin: a novel marker for neurons, certain neuroendocrine cells, and their neoplasms. Hum Pathol (1986) 1.07
Synthesis, characterization, and biological properties of cyanine-labeled somatostatin analogues as receptor-targeted fluorescent probes. Bioconjug Chem (2001) 1.06
Refractory sprue syndrome with clonal intraepithelial lymphocytes evolving into overt enteropathy-type intestinal T-cell lymphoma. Digestion (2000) 1.06
Localisation of neuroendocrine tumours of the upper gastrointestinal tract. Gut (1994) 1.04
Association of TLR7 single nucleotide polymorphisms with chronic HCV-infection and response to interferon-a-based therapy. J Viral Hepat (2008) 1.02
Synaptophysin: a reliable marker for medulloblastomas. Virchows Arch A Pathol Anat Histopathol (1987) 1.01
Analysis of sporadic neuroendocrine tumours of the enteropancreatic system by comparative genomic hybridisation. Gut (2001) 1.00
Anti-ghrelin Spiegelmer NOX-B11 inhibits neurostimulatory and orexigenic effects of peripheral ghrelin in rats. Gut (2005) 1.00
Retinoids: effects on growth, differentiation, and nuclear receptor expression in human pancreatic carcinoma cell lines. Gastroenterology (1995) 0.99
A matter of the heart: myocardial metastases in neuroendocrine tumors. Horm Metab Res (2010) 0.97
Genetic factors determine extent of bone loss in inflammatory bowel disease. Gastroenterology (2000) 0.97
Identification of a distinct 9S form of soluble clathrin in cultured cells and tissues. Exp Cell Res (1986) 0.97
Endoscopic ultrasonography of neuroendocrine tumours. Digestion (2000) 0.97
Effects of exogenous zinc supplementation on intestinal epithelial repair in vitro. Eur J Clin Invest (2000) 0.97
Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors. Digestion (1999) 0.97
Oesophageal transport of solid dosage forms depends on body position, swallowing volume and pharyngeal propulsion velocity. Neurogastroenterol Motil (2004) 0.96
Activation of protein kinase Calpha inhibits growth of pancreatic cancer cells via p21(cip)-mediated G(1) arrest. J Cell Sci (2000) 0.96
Decrease of natural killer cell activity and monokine production in peripheral blood of patients treated with recombinant tumor necrosis factor. Blood (1988) 0.96
Neuroendocrine tumors. Biotherapy. Best Pract Res Clin Endocrinol Metab (2007) 0.95
Dynamics of GB virus C viremia early after orthotopic liver transplantation indicates extrahepatic tissues as the predominant site of GB virus C replication. Hepatology (1999) 0.95
Sp1 and CREB mediate gastrin-dependent regulation of chromogranin A promoter activity in gastric carcinoma cells. J Biol Chem (1998) 0.95
Neuroendocrine tumors of the gastro-entero-pancreatic system: the role of early diagnosis, genetic testing and preventive surgery. Dig Dis (2002) 0.95
Glucagon increases circulating fibroblast growth factor 21 independently of endogenous insulin levels: a novel mechanism of glucagon-stimulated lipolysis? Diabetologia (2012) 0.94
Loss of the coxsackie and adenovirus receptor contributes to gastric cancer progression. Br J Cancer (2009) 0.94
[Neuroendocrine tumours of the gastrointestinal tract]. Z Gastroenterol (2004) 0.93
An amphicrine pancreatic cell line: AR42J cells combine exocrine and neuroendocrine properties. Eur J Cell Biol (1992) 0.93
Detection of G-protein heterotrimers on large dense core and small synaptic vesicles of neuroendocrine and neuronal cells. Eur J Cell Biol (1994) 0.93
Clinical relevance of transabdominal ultrasonography and magnetic resonance imaging in patients with inflammatory bowel disease of the terminal ileum and large bowel. Inflamm Bowel Dis (2004) 0.93
Oxidative stress activates the human histidine decarboxylase promoter in AGS gastric cancer cells. J Biol Chem (1998) 0.93
Long-term failure of endoscopic suturing in the treatment of gastroesophageal reflux: a prospective follow-up study. Endoscopy (2005) 0.92
Electrogastrography as a diagnostic tool for delayed gastric emptying in functional dyspepsia and irritable bowel syndrome. Neurogastroenterol Motil (2003) 0.92
Downregulation of the coxsackie and adenovirus receptor in cancer cells by hypoxia depends on HIF-1alpha. Cancer Gene Ther (2009) 0.91
Vesicular monoamine transporter 2 as a marker of gastric enterochromaffin-like cell tumors. Virchows Arch (2000) 0.90
Combined imaging techniques for pancreatic cancer. Lancet (2000) 0.90
Investigation of gastrointestinal transport by magnetic marker localization. Biomed Tech (Berl) (2002) 0.90
Mutations in the MEN I gene in sporadic neuroendocrine tumours of gastroenteropancreatic system. Lancet (1997) 0.90
Reduced bone mineral density and unbalanced bone metabolism in patients with inflammatory bowel disease. Inflamm Bowel Dis (1998) 0.90
Impact of FDG-PET/MRI image fusion on the detection of pancreatic cancer. Pancreatology (2006) 0.90
Loss of Coxsackie and adenovirus receptor downregulates alpha-catenin expression. Br J Cancer (2009) 0.90
Endocrine tumours of the gastrointestinal tract. Management of metastatic endocrine tumours. Best Pract Res Clin Gastroenterol (2005) 0.89
Primary and secondary hepatic manifestation of neuroendocrine tumors. Langenbecks Arch Surg (2000) 0.89
Review on the influence of stress on immune mediators, neuropeptides and hormones with relevance for inflammatory bowel disease. Digestion (2002) 0.89
The small GTP-binding protein, Rab6p, is associated with both Golgi and post-Golgi synaptophysin-containing membranes during synaptogenesis of hypothalamic neurons in culture. J Cell Sci (1993) 0.89
Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites. Eur J Cancer (1991) 0.89
Expression of functional GABAA receptors in neuroendocrine gastropancreatic cells. Pflugers Arch (1995) 0.89
Orexin A stimulates glucose uptake, lipid accumulation and adiponectin secretion from 3T3-L1 adipocytes and isolated primary rat adipocytes. Diabetologia (2011) 0.88
Interferon-alpha delays S-phase progression in human hepatocellular carcinoma cells via inhibition of specific cyclin-dependent kinases. Hepatology (2001) 0.88
Standardisation of imaging in neuroendocrine tumours: results of a European delphi process. Eur J Radiol (2001) 0.88
ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas. Neuroendocrinology (2016) 0.88
A study for the evaluation of safety and tolerability of intravenous high-dose iron sucrose in patients with iron deficiency anemia due to gastrointestinal bleeding. Z Gastroenterol (2004) 0.87
Bone loss in patients with inflammatory bowel disease is less than expected: a follow-up study. Scand J Gastroenterol (1999) 0.86